SC
DICE

Steven Cohen’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Steven Cohen’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-398,000
Closed -$7.61M – 1713
2022
Q1 		$7.61M Buy
+398,000
New +$7.1M 0.03% 585

Other funds holding DICE

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Steven Cohen's DICE Position: Q2 2022 in Review

Steven Cohen sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q2 2022, closing a stake of 398,000 shares — an estimated $7.61M sold.

Steven Cohen first reported a position in DICE in Q1 2022 and held it in 1 quarter. The position peaked at $7.61M in Q1 2022. 80 funds tracked by Wall St. Rank hold DICE as of Q2 2022.

  • Steven Cohen reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Steven Cohen sold 398,000 DICE Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $7.61M.
  • Steven Cohen first reported a position in DICE Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Steven Cohen's DICE Therapeutics, Inc. Common Stock position peaked at $7.61M in Q1 2022.
  • 80 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Point72 Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.